{"id":472,"date":"2003-03-01T12:07:00","date_gmt":"2003-03-01T11:07:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2003\/nochmals-rituximab-zur-therapie-der-idiopathischen-membranoesen-glomerulopathie"},"modified":"2003-03-01T12:07:00","modified_gmt":"2003-03-01T11:07:00","slug":"nochmals-rituximab-zur-therapie-der-idiopathischen-membranoesen-glomerulopathie","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2003\/nochmals-rituximab-zur-therapie-der-idiopathischen-membranoesen-glomerulopathie","title":{"rendered":"Nochmals: Rituximab zur Therapie der idiopathischen membran\u00f6sen Glomerulopathie"},"content":{"rendered":"<p>Die Dosierung von Rituximab in der von uns besprochenen Arbeit von G. Remuzzi ist im Lancet-Original (s. AMB 2002, 36, 87) mi\u00dfverst\u00e4ndlich mitgeteilt. Nach pers\u00f6nlicher Mitteilung des Autors betrug sie 375 mg\/m2 als Infusion viermal in der Woche. Zu beachten ist, da\u00df Rituximab f\u00fcr diese Indikation nicht zugelassen ist.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Die Dosierung von Rituximab in der von uns besprochenen Arbeit von G. Remuzzi ist im Lancet-Original (s. AMB 2002, 36, 87) mi\u00dfverst\u00e4ndlich mitgeteilt. Nach pers\u00f6nlicher Mitteilung des Autors betrug sie 375 mg\/m2 als Infusion viermal in der Woche. Zu beachten ist, da\u00df Rituximab f\u00fcr diese Indikation nicht zugelassen ist.<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[805,798],"class_list":["post-472","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-membranoese-glomerulopathie","tag-rituximab"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/472","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=472"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/472\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=472"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=472"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=472"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}